LY2 - Cell Line (ID:51095)
| HMS LINCS ID: | 51095 |
| Name: | LY2 |
| Alternative Names: | LY 2 |
| LINCS ID: | LCL-2076 |
| Alternative ID: | CLO_0009913 |
| Parent Cell Line: | |
| Reference Source: | Mark Lippman (National Cancer Institute) |
| Organism: | Homo sapiens |
| Organ: | breast |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | |
| Details of Disease: | |
| Production Details: | The cell line was selected by increasing the concentration of LY 117018, a potent antiestrogen that inhibits cell growth at concentrations as low as 10(-10) M, in the growth medium in a stepwise manner from 10(-8) to 10(-6) M as the cells become resistant. |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | |
| Verification Reference Profile: | |
| Growth Properties: | |
| Recommended Culture Conditions: | |
| Relevant Citations: | PMID 4029083 |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2013-07-30 |
| Most Recent Update: | 2016-07-12 |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20120 | Metrics other than potency reveal systematic variation in responses to cancer drugs | Analysis |
| 20268 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. | Analysis |
| 20269 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. | Analysis |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
|---|---|---|---|
| 51095-1 | Georgetown University |